Case-Based Roundtable Meetings Spotlight
Case-Based Roundtable Meetings Spotlight: May 2023
Case-Based Roundtable Meetings Spotlight: April 2, 2023
Case-Based Roundtable Meetings Spotlight: April 1, 2023
Case-Based Roundtable Meetings Spotlight: March 2, 2023
Volume: 6
Issue: 4
Case-Based Roundtable Meetings Spotlight: March 1, 2023
Volume: 6
Issue: 3
Case-Based Roundtable Meetings Spotlight: February 2023
Volume: 6
Issue: 2
Case-Based Roundtable Meetings Spotlight: January 2023
Case-Based Roundtable Meetings Spotlight: December 2, 2022
Case-Based Roundtable Meetings Spotlight: December 1, 2022
Case-Based Roundtable Meetings Spotlight: November 1, 2022
Case-Based Roundtable Meetings Spotlight: November 2, 2022
October 2, 2022
October 1 2022
Case-Based Roundtable Meetings Spotlight: September 2022
Case-Based Roundtable Meetings Spotlight: August 2022
Volume: 5
Issue: 11
Case-Based Roundtable Meetings Spotlight: July 2, 2022
Case-Based Roundtable Meetings Spotlight: July 1, 2022
Case-Based Roundtable Meetings Spotlight: June 2022
Case-Based Roundtable Meetings Spotlight: May 2022
Case-Based Roundtable Meetings Spotlight: April 2 2022
Case-Based Roundtable Meetings Spotlight: April 1 2022
Case-Based Roundtable Meetings Spotlight: March 2022
Case-Based Roundtable Meetings Spotlight: February 1, 2022
Case-Based Roundtable Meetings Spotlight: February 2, 2022
Case-Based Roundtable Meetings Spotlight: January 1, 2022
Case-Based Roundtable Meetings Spotlight: December 2, 2021
Case-Based Roundtable Meetings Spotlight December 1, 2021
Case-Based Roundtable Meeting Spotlight November 1 2021
Case-Based Roundtable Meeting Spotlight November 2, 2021
Case-Based Roundtable Meeting Spotlight October 1 2021
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5